Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet

Topics

Medicine

Cancer Oncology

Epidemiology

Pathology

Internal Medicine

Show all topics

DOI

10.1016/s0140-6736(16)32453-9

Other Formats

PDF